



PULEVA BIOTECH EXXENTIA WINS THE GOLD AWARD IN THE CPhI INNOVATION 2009 CONTEST

PULEVA BIOTECH EXXENTIA has taken the Gold in the Innovation 2009 Award contest held during the CPhI worldwide Fair hosted in Madrid 13-15th October 2009. The award was granted to PULEVA BIOTECH EXXENTIA for the investigation project on the Hereditum™ application in mastitis.

Hereditum™ is a group of probiotic bacteria derived from human breast milk that is capable of being used in infant nutrition products and play a very important role in lactating babies immune defenses as well as other health areas. These bacteria were discovered and patented by PULEVA BIOTECH EXXENTIA in 2005.

More than 300 projects were submitted to compete for these prizes with only six reaching the final round, some of them presented by well known companies such as Cambrex, BASF, Novozymes, and KitoZyme. Arjan Geerlings, PULEVA BIOTECH EXXENTIA Director of Nutrition, was entrusted with defending the importance of the project and later picked up the top award in person at the ceremony. The Silver and Bronze Awards were given to Cambrex and Novozymes respectively.

The CPhI Innovation Awards are some of the most prestigious in the investigation sector. CPhI Worldwide is the market leader for the global pharmaceuticals ingredients industry and related sectors. More than 25,000 professionals gather together and a total of 1,430 companies from 125 countries attend regularly.



Jayne Muir (Cambrex), Arjan Geerlings (PULEVA BIOTECH EXXENTIA Exxentia), Dave Mead (Novozymes)